Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583131 | 0.93 | TACR1 (0.34) | MEN1KMT2A | |
| SCHEMBL7458038 | 0.91 | TACR1 (0.36) | MEN1KMT2A | |
| SCHEMBL4274371 | 0.90 | GSTP1 (0.40) | PDPK1MTORGSTP1 | |
| SCHEMBL13657214 | 0.90 | GSTP1 (0.40) | PDPK1MTORGSTP1 | |
| SCHEMBL1521120 | 0.86 | MEN1 (0.32) | MEN1KMT2APDPK1MTORMAPT | |
| SCHEMBL1521133 | 0.86 | MEN1 (0.32) | MEN1KMT2APDPK1MTORMAPT | |
| SCHEMBL13129875 | 0.83 | PDPK1 (0.37) | MEN1KMT2APDPK1MTORMAPT | |
| SCHEMBL13129819 | 0.83 | PDPK1 (0.37) | MEN1KMT2APDPK1MTORMAPT | |
| SCHEMBL5691292 | 0.81 | L3MBTL1 (0.35) | PDPK1MTORMAPTCYP2C19 | |
| SCHEMBL584139 | 0.81 | PDPK1 (0.40) | PDPK1MTORMAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417144-B1 | SYNTHESIS OF 2'-O-FUCOSYLLACTOSE | GLYCOM AS (DK) | 2017-08-23 | — | — | EP | disclosed |
| US-8927698-B2 | Method for the synthesis of a trisaccharide | GLYCOM A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-20120116065-A1 | NOVEL METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE | GLYCOM A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| EP-2417144-A1 | SYNTHESIS OF 2 ' -O-FUCOSYLLACTOSE | Glycom A/S (DK) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115935-A1 | SYNTHESIS OF 2 ' -O-FUCOSYLLACTOSE | GLYCOM A/S (DK) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116065-A1 | NOVEL METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE | FUT6, FUT5, GALE | MEN1 1097/4885KMT2A 3891/4885PDPK1 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.